{"result": "(\"entity\"<|>FIBROSIS QUÍSTICA<|>EVENT<|>Fibrosis quística is a complex disease that requires multidisciplinary management and is associated with complications such as malnutrition and DRFQ, which worsen prognosis.)\n##\n(\"entity\"<|>PACIENTE<|>PERSON<|>The patient is an adult with cystic fibrosis who has experienced weight loss and requires nutritional support through enteral nutrition (NE).)\n##\n(\"entity\"<|>ENZIMAS PANCREÁTICAS<|>ORGANIZATION<|>Pancreatic enzymes are administered to patients with cystic fibrosis to aid in digestion and prevent malnutrition.)\n##\n(\"entity\"<|>FÓRMULA POLIMÉRICA<|>ORGANIZATION<|>A type of nutritional formula used for enteral nutrition, specifically tailored for diabetic patients.)\n##\n(\"entity\"<|>NUTRICIÓN ENTERAL<|>EVENT<|>Enteral nutrition (NE) is a method of delivering nutrition directly to the stomach or intestines, used for patients with cystic fibrosis.)\n##\n(\"entity\"<|>VITAMINAS LIPOSOLUBLES<|>ORGANIZATION<|>Fat-soluble vitamins that need to be monitored in patients with cystic fibrosis to prevent deficiencies.)\n##\n(\"relationship\"<|>PACIENTE<|>FIBROSIS QUÍSTICA<|>The patient is diagnosed with cystic fibrosis, which requires specific management and nutritional support.<|>9)\n##\n(\"relationship\"<|>PACIENTE<|>NUTRICIÓN ENTERAL<|>The patient is receiving enteral nutrition due to complications from cystic fibrosis.<|>8)\n##\n(\"relationship\"<|>PACIENTE<|>FÓRMULA POLIMÉRICA<|>The patient is using a specific polymeric formula for enteral nutrition tailored for diabetics.<|>7)\n##\n(\"relationship\"<|>PACIENTE<|>ENZIMAS PANCREÁTICAS<|>The patient requires pancreatic enzymes to aid digestion due to cystic fibrosis-related malabsorption.<|>8)\n##\n(\"relationship\"<|>PACIENTE<|>VITAMINAS LIPOSOLUBLES<|>The patient needs monitoring of fat-soluble vitamins to prevent deficiencies associated with cystic fibrosis.<|>6)\n##\n(\"relationship\"<|>FIBROSIS QUÍSTICA<|>NUTRICIÓN ENTERAL<|>Cystic fibrosis often necessitates enteral nutrition due to malabsorption issues.<|>7)\n##\n(\"relationship\"<|>FIBROSIS QUÍSTICA<|>ENZIMAS PANCREÁTICAS<|>Cystic fibrosis leads to exocrine pancreatic insufficiency, requiring enzyme supplementation.<|>8)\n##\n(\"relationship\"<|>FIBROSIS QUÍSTICA<|>VITAMINAS LIPOSOLUBLES<|>Cystic fibrosis can cause malabsorption of fat-soluble vitamins, necessitating monitoring.<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: a la situación clínica del paciente. La gastrostomía está indicada en pacientes adultos\ncon FQ que presenten un IMC bajo (IMC<18kg/m2) de forma mantenida o una pérdida de\npeso superior al 5% de forma mantenida, como era el caso de nuestro paciente. Actual-\nmente, no existe ninguna indicación clara en lo que respecta a la fórmula de elección\nde la NE para el paciente con FQ6, debiéndose adecuar a la situación individualizada de\ncada paciente, si bien, las fórmulas poliméricas suelen ser bien toleradas. Otra opción\nserían las fórmulas poliméricas específicas para pacientes diabéticos o bien las fór-\nmulas peptídicas, con mayor contenido en MCT, que ayuda a controlar la esteatorrea.\nLas características de las 3 fórmulas se comparan en la Tabla 4. En el caso de nuestro\npaciente inicialmente llevó una fórmula polimérica normocalórica normoproteica es-\npecífica para diabéticos, que posteriormente se cambió por una fórmula polimérica\nhipercalórica hiperproteica específica para diabéticos dado que no toleraba volúmenes\nmayores. También, durante el seguimiento, presentó una mayor esteatorrea con dicha\nfórmula por lo que se probó con una NE peptídica, con empeoramiento marcada del\ncontrol glucémico, por lo que actualmente sigue llevando una fórmula polimérica es-\npecífica para diabéticos.\n\nHay que tener en cuenta, en estos pacientes que la malabsorción debida a la\ninsuficiencia pancreática exocrina obliga también a ajustar la dosis de enzimas pan-\ncreáticas durante la administración de la NE, recomendándose administrar la mitad de\nlas enzimas pancreáticas antes y la otra mitad una vez ha finalizado la NE. El ajuste\nde las enzimas pancreáticas es esencial para evitar mayor grado de desnutrición y dé-\nficit de vitaminas liposolubles. Se debe monitorizar de forma frecuente, cada 3-6m los\nniveles de vitaminas liposolubles, así como los niveles de zinc, ácido fólico, vitamina\nB12, calcio, y hierro. Dicha monitorización no se ha abordado en el capítulo actual para\najustarse a las normas de edición.\n\n## Conclusiones\n\nLa fibrosis quística es una enfermedad compleja, que requiere un manejo\nmultidisciplinar. Con frecuencia aparecen complicaciones asociadas a la misma, como\nla desnutrición y la DRFQ que empeoran el pronóstico. Ambas no pueden ser tratadas\nde forma independiente ya que están estrechamente vinculadas.\n---\n# Anexos\n\n## Tabla 1.\n### Evolución del peso, talla, IMC, control glucémico del paciente y pautas de NE empleadas\n\n| AÑO | TALLA (cm) | PESO (kg) | IMC (kg/m²) | HbA1c (%) | PAUTA DE NE |\n|-----|------------|-----------|-------------|-----------|-------------|\n| 2011 | 152,5 | 38,7 | 16,6 | 8,1 | Fórmula polimérica NC (1,0kcaL/mL) NP específica de diabético. |\n| 2011 | 152,5 | 40,6 | 17,5 | 8,5 | Se cambia a Fórmula polimérica HC (1.5kcaL/ml) HP específica para diabéticos 1000mL |\n| 2012 | 153,5 | 42,8 | 18,2 | 9 | = |\n| 2013 | 155,5 | 45,7 | 18,9 | 8,1 | Fórmula peptídica HC/HP (1,5kcaL/mL) con 68% de grasas en forma de MCT, 1000mL (1500kcaL) |\n| 2014 | 155,5 | 43,5 | 18 | 11,7 | Fórmula polimérica HC/HP (1.5kcaL/ml) específica para diabéticos 1000mL al día |\n| 2015 | 155,5 | 42,4 | 17,5 | 8,9 | = |\n| 2016 | 156 | 39,3 | 16,1 | 10,3 | Fórmula polimérica HC/HP (1.5kcaL/ml) específica para diabéticos 1500mL al día |\n| 2017 | 157 | 40,5 | 16,4 | 8,3 | = |\n| 2018 | 157,5 | 42,9 | 17,3 | 7,2 | Fórmula polimérica HC (1.5kcaL/ml) HP específica para diabéticos 1000mL |\n\n## Tabla 2: Cl\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}